Compare Ascendis Pharma A/S (ASND) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Chipotle Mexican Grill, Inc. — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Chipotle Mexican Grill, Inc. trades at $36.42 (market cap $45.22B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 2.5× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | CMG | |
|---|---|---|
Market Cap | $17.74B | $45.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $56.00 |
52-Week Low | $163.32 | $28.17 |
Enterprise Value | $18.11B | $49.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Chipotle Mexican Grill (CMG) trades at $35.25, up 1.88% on the day, with strong analyst support and consistent earnings beats. The stock shows bullish technical signals with support at $34 and resistance at $35. Revenue grew to $11.93 billion in 2025, with a net income margin of 11.96%, though margins have narrowed slightly from prior years. Recent news highlights operational focus and menu innovation as growth drivers.
Outlook remains positive with a $40.46 consensus price target, but risks include cost pressures and competitive threats. The stock offers growth potential through expansion and operational excellence, yet investors should monitor margin trends and consumer spending shifts in the volatile restaurant sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
